IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 2, Issue 4 (2021)
J Clinic Care Skill 2021, 2(4): 195-199 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
gharghani M, Rezaei-Matehkolaei A, Shokoohi G, Taghavi J, Nouripour-Sisakht S. in vitro Activity of Seven Antifungals against Different Clinical Candida Species. J Clinic Care Skill 2021; 2 (4) :195-199
URL: http://jccs.yums.ac.ir/article-1-119-en.html
URL: http://jccs.yums.ac.ir/article-1-119-en.html
1- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran, School of Medicine
2- Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, School of Medicine
3- Department of Medical Parasitology and Mycology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran, School of Medicine
4- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran , nooripoor8561@gmail.com
2- Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, School of Medicine
3- Department of Medical Parasitology and Mycology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran, School of Medicine
4- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran , nooripoor8561@gmail.com
Abstract: (882 Views)
Aims: This study aimed to determine the antifungal susceptibility profile of Candida spp. with different sources.
Methods: This descriptive study was conducted in the Department of Medical Mycology of Yasuj, Iran, from 2018 to 2019. Seventy-six Candida isolates recovered from different samples were used for antifungal profiles. Candida spp. isolates were identified at the species level based on molecular methods. The antifungal susceptibility tests with fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, nystatin, and caspofungin were assessed according to the Clinical and Laboratory Standards Institute broth microdilution method.
Findings: Our study showed that all isolates species were sensitive to antifungal drugs except for 3 (3.9%) isolates resistant to fluconazole. Among the In vitro activity of triazoles against all isolates tested, voriconazole had the lowest minimum inhibitory concentration ranges of 0.5-0.015µg/ml. According to the minimum inhibitory concentration of 50%, amphotericin B (0.25μg/ml) and nystatin (0.0625μg/ml) was the most active polyenes against other Candida species.
Conclusion: Generally, the clinical correlation between the minimum inhibitory concentration value of different antifungals and different Candida spp. isolates are necessary because the resistance profile of Candida spp. is varied and dependent on the different variables.
Methods: This descriptive study was conducted in the Department of Medical Mycology of Yasuj, Iran, from 2018 to 2019. Seventy-six Candida isolates recovered from different samples were used for antifungal profiles. Candida spp. isolates were identified at the species level based on molecular methods. The antifungal susceptibility tests with fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, nystatin, and caspofungin were assessed according to the Clinical and Laboratory Standards Institute broth microdilution method.
Findings: Our study showed that all isolates species were sensitive to antifungal drugs except for 3 (3.9%) isolates resistant to fluconazole. Among the In vitro activity of triazoles against all isolates tested, voriconazole had the lowest minimum inhibitory concentration ranges of 0.5-0.015µg/ml. According to the minimum inhibitory concentration of 50%, amphotericin B (0.25μg/ml) and nystatin (0.0625μg/ml) was the most active polyenes against other Candida species.
Conclusion: Generally, the clinical correlation between the minimum inhibitory concentration value of different antifungals and different Candida spp. isolates are necessary because the resistance profile of Candida spp. is varied and dependent on the different variables.
Article Type: Original Research |
Subject:
Special
Received: 2021/11/24 | Accepted: 2021/12/25 | Published: 2022/01/31
Received: 2021/11/24 | Accepted: 2021/12/25 | Published: 2022/01/31
References
1. Brandt ME. Candida and candidiasis. Emerg Infect Dis. 2002;8(8):876. [DOI:10.3201/eid0808.020059] [PMCID]
2. Dabas PS. An approach to etiology, diagnosis and management of different types of candidiasis. J Yeast Fungal Res. 2013;4(6):63-74. [LINK]
3. Kullberg BJ, Arendrup MC. Invasive candidiasis. New England J Med. 2015;373(15):1445-56. [DOI:10.1056/NEJMra1315399] [PMID]
4. Gharaghani M, Rezaei‐Matehkolaei A, Hardani AK, Zarei Mahmoudabadi A. Genotypic diversity and antifungal susceptibility pattern of Candida albicans species isolated from hospitalized paediatric patients with urinary tract infection in Iran. J Appl Microbiol. 2021;131(2):1017-27. [DOI:10.1111/jam.15006] [PMID]
5. Shokoohi G, Rasekh-Jahromi A, Solhjoo K, Hasannezhad A, Nouripour-Sisakht S, Ahmadi B, et al. Molecular characterization and antifungal susceptibility of Candida species isolated from vulvovaginitis in Jahrom city, south of Iran. Jundishapur J Microbiol. 2020;13(10):e106825. [DOI:10.5812/jjm.106825]
6. Deorukhkar SC, Saini S, Mathew S. Non-albicans Candida infection: An emerging threat. Interdiscip Perspect Infect Dis. 2014;2014:615958. [DOI:10.1155/2014/615958] [PMID] [PMCID]
7. Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: An evidence-based review. Core Evid. 2014;9:113-24. [DOI:10.2147/CE.S49629] [PMID] [PMCID]
8. Gharaghani M, Hivary S, Taghipour S, Zarei-Mahmoudabadi A. Luliconazole, a highly effective imidazole, against Fusarium species complexes. Med Microbiol Immunol. 2020;209(5):603-12. [DOI:10.1007/s00430-020-00672-4] [PMID]
9. Kanafani ZA, Perfect JR. Resistance to antifungal agents: Mechanisms and clinical impact. Clin Infect Dis. 2008;46(1):120-8. [DOI:10.1086/524071] [PMID]
10. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: Effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis. 2009;64(3):354-6. [DOI:10.1016/j.diagmicrobio.2009.03.021] [PMID]
11. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations. J Clin Microbiol. 2000;38(4):1563-8. [DOI:10.1128/JCM.38.4.1563-1568.2000] [PMID]
12. Yan L, Wang X-d, Seyedmousavi S, Yuan J-n, Abulize P, Pan W-h, et al. Antifungal susceptibility profile of Candida albicans isolated from vulvovaginal candidiasis in Xinjiang province of China. Mycopathologia. 2019;184(3):413-22. [DOI:10.1007/s11046-018-0305-2] [PMID]
13. Gharaghani M, Ahmadi B, Taheripour Sisakht M, Ilami O, Aramesh S, Mouhamadi F, et al. Identification of Candida species isolated from vulvovaginal candidiasis patients by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in Yasuj southwestern Iran. Jundishapur J Microbiol. 2018;11(8):e65359. [DOI:10.5812/jjm.65359]
14. Sabz G, Gharaghani M, Mirhendi H, Ahmadi B, Gatee MA, Sisakht MT, et al. Clinical and microbial epidemiology of otomycosis in the city of Yasuj, southwest Iran, revealing Aspergillus tubingensis as the dominant causative agent. J Med Microbiol. 2019;68(4):585-90. [DOI:10.1099/jmm.0.000948] [PMID]
15. Procop GW, Dufresne PJ, Berkow E, Castanheira M, Fuller J, Hanson KE, et al. M59: Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 3rd edition. Wayne: Clinical and Laboratory Standards Institute; 2020. [LINK]
16. Alexander BD, Procop GW, Dufresne PJ, Fuller J, Ghannoum MA, Hanson KE, et al. M27: Reference method for broth dilution antifungal susceptibility testing of yeasts. 4th edition. Wayne: Clinical and Laboratory Standards Institute; 2017. [LINK]
17. Da Matta DA, de Almeida LP, Machado AM, Azevedo AC, Kusano EJU, Travassos NF, et al. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: Results of a multicenter study conducted in Sao Paulo, Brazil, 1995-2003. Diagn Microbiol Infect Dis. 2007;57(4):399-404. [DOI:10.1016/j.diagmicrobio.2006.10.011] [PMID]
18. Lyon GM, Karatela S, Sunay S, Adiri Y, Candida Surveillance Study Investigators. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010;48(4):1270-5. [DOI:10.1128/JCM.02363-09] [PMID] [PMCID]
19. Wang FJ, Zhang D, Liu ZH, Wu WX, Bai HH, Dong HY. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin Med J (Engl). 2016;129(10):1161-5. [DOI:10.4103/0366-6999.181964] [PMID] [PMCID]
20. Bitew A, Abebaw Y. Vulvovaginal candidiasis: Species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018;18(1):94. [DOI:10.1186/s12905-018-0607-z] [PMID] [PMCID]
21. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43(5):2155-62. [DOI:10.1128/JCM.43.5.2155-2162.2005] [PMID] [PMCID]
22. Blignaut E, Messer S, Hollis R, Pfaller M. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis. 2002;44(2):169-74. [DOI:10.1016/S0732-8893(02)00440-6]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |